Amarin (AMRN) Competitors $0.49 0.00 (0.00%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends AMRN vs. HRTX, GBIO, YMAB, RLAY, ERAS, EOLS, PLRX, CRON, PRTA, and REPLShould you be buying Amarin stock or one of its competitors? The main competitors of Amarin include Heron Therapeutics (HRTX), Generation Bio (GBIO), Y-mAbs Therapeutics (YMAB), Relay Therapeutics (RLAY), Erasca (ERAS), Evolus (EOLS), Pliant Therapeutics (PLRX), Cronos Group (CRON), Prothena (PRTA), and Replimune Group (REPL). These companies are all part of the "pharmaceutical products" industry. Amarin vs. Heron Therapeutics Generation Bio Y-mAbs Therapeutics Relay Therapeutics Erasca Evolus Pliant Therapeutics Cronos Group Prothena Replimune Group Amarin (NASDAQ:AMRN) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, community ranking, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends. Does the media prefer AMRN or HRTX? In the previous week, Heron Therapeutics had 6 more articles in the media than Amarin. MarketBeat recorded 7 mentions for Heron Therapeutics and 1 mentions for Amarin. Heron Therapeutics' average media sentiment score of 0.09 beat Amarin's score of -1.00 indicating that Heron Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amarin 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Heron Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher earnings and valuation, AMRN or HRTX? Amarin has higher revenue and earnings than Heron Therapeutics. Heron Therapeutics is trading at a lower price-to-earnings ratio than Amarin, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmarin$306.91M0.66-$59.11M-$0.09-5.49Heron Therapeutics$137.74M1.24-$110.56M-$0.18-6.22 Is AMRN or HRTX more profitable? Amarin has a net margin of -16.33% compared to Heron Therapeutics' net margin of -20.31%. Heron Therapeutics' return on equity of 0.00% beat Amarin's return on equity.Company Net Margins Return on Equity Return on Assets Amarin-16.33% -7.22% -4.96% Heron Therapeutics -20.31%N/A -12.72% Which has more volatility & risk, AMRN or HRTX? Amarin has a beta of 1.92, indicating that its stock price is 92% more volatile than the S&P 500. Comparatively, Heron Therapeutics has a beta of 1.81, indicating that its stock price is 81% more volatile than the S&P 500. Do analysts rate AMRN or HRTX? Heron Therapeutics has a consensus target price of $5.67, suggesting a potential upside of 405.95%. Given Heron Therapeutics' higher probable upside, analysts plainly believe Heron Therapeutics is more favorable than Amarin.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amarin 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Heron Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals hold more shares of AMRN or HRTX? 22.3% of Amarin shares are owned by institutional investors. Comparatively, 80.0% of Heron Therapeutics shares are owned by institutional investors. 2.0% of Amarin shares are owned by company insiders. Comparatively, 5.8% of Heron Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the MarketBeat Community favor AMRN or HRTX? Amarin received 182 more outperform votes than Heron Therapeutics when rated by MarketBeat users. Likewise, 74.36% of users gave Amarin an outperform vote while only 69.10% of users gave Heron Therapeutics an outperform vote. CompanyUnderperformOutperformAmarinOutperform Votes84474.36% Underperform Votes29125.64% Heron TherapeuticsOutperform Votes66269.10% Underperform Votes29630.90% SummaryAmarin beats Heron Therapeutics on 9 of the 17 factors compared between the two stocks. Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…Get Your Free Gold Guide Get Amarin News Delivered to You Automatically Sign up to receive the latest news and ratings for AMRN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AMRN vs. The Competition Export to ExcelMetricAmarinPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$201.52M$6.48B$5.05B$8.87BDividend YieldN/A8.12%4.97%4.06%P/E Ratio-5.495.5697.3414.18Price / Sales0.66348.141,218.4289.42Price / CashN/A22.1533.5132.79Price / Book0.387.885.805.12Net Income-$59.11M$153.61M$119.07M$225.99M7 Day Performance-4.92%-2.00%-1.83%-1.32%1 Month Performance-14.02%-7.47%-3.64%0.60%1 Year Performance-35.72%31.80%31.62%26.23% Amarin Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AMRNAmarin0.1111 of 5 stars$0.49flatN/A-37.4%$201.52M$306.91M-5.49360Negative NewsHRTXHeron Therapeutics3.9688 of 5 stars$1.12-5.9%$5.67+406.0%-13.8%$180.99M$137.74M-6.22300Analyst DowngradeShort Interest ↓GBIOGeneration Bio3.359 of 5 stars$1.35-2.9%$7.50+455.6%+7.1%$92.84M$5.90M0.00150YMABY-mAbs Therapeutics3.3273 of 5 stars$10.54-2.9%$21.38+102.8%+100.8%$486.41M$84.82M0.00150Analyst ForecastRLAYRelay Therapeutics3.2712 of 5 stars$4.66-2.9%$21.22+355.4%-44.5%$803.44M$25.55M0.00304Gap DownHigh Trading VolumeERASErasca2.8027 of 5 stars$2.64-5.4%$6.08+130.4%+17.3%$788.81MN/A0.00126Analyst ForecastAnalyst RevisionEOLSEvolus4.0221 of 5 stars$12.63+1.9%$23.00+82.1%+28.4%$784.55M$202.09M0.00170Positive NewsPLRXPliant Therapeutics3.4847 of 5 stars$12.73-0.5%$40.57+218.7%-11.4%$778.32M$1.58M0.0090CRONCronos Group1.7734 of 5 stars$2.01-1.0%$3.00+49.3%-3.8%$776.06M$87.24M0.00356PRTAProthena1.6436 of 5 stars$14.40+2.5%$61.86+329.6%-57.8%$756.01M$91.37M0.00173Analyst DowngradeAnalyst RevisionREPLReplimune Group4.2366 of 5 stars$11.23+2.6%$16.80+49.6%+10.3%$749.17MN/A0.00210 Related Companies and Tools Related Companies Heron Therapeutics Alternatives Generation Bio Alternatives Y-mAbs Therapeutics Alternatives Relay Therapeutics Alternatives Erasca Alternatives Evolus Alternatives Pliant Therapeutics Alternatives Cronos Group Alternatives Prothena Alternatives Replimune Group Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AMRN) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amarin Co. plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Amarin With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AMRN Stock Alerts